CLINICAL TRIALS PROFILE FOR MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

All Clinical Trials for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Development Center for Biotechnology, Taiwan	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Program Office, National Science & Technology, Biotechnology & Pharmaceuticals	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	Taipei Veterans General Hospital, Taiwan	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗	Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease	Unknown status	National Taiwan University Hospital	Phase 2	2005-09-01	A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00181298 ↗	Memantine in Systemic Lupus Erythematosus	Completed	Forest Laboratories	N/A	2006-03-01	Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
NCT00181298 ↗	Memantine in Systemic Lupus Erythematosus	Completed	Johns Hopkins University	N/A	2006-03-01	Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.

Clinical Trial Conditions for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Condition Name

Condition Name for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Intervention	Trials
Alzheimer's Disease	10
Alzheimer Disease	5
Dementia	3
Dementia, Alzheimer Type	2

Condition MeSH

Condition MeSH for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Intervention	Trials
Alzheimer Disease	20
Dementia	5
Cognitive Dysfunction	2
Multiple Sclerosis, Chronic Progressive	1

Clinical Trial Locations for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Trials by Country

Trials by Country for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Location	Trials
United States	93
Spain	6
Canada	5
France	4
United Kingdom	4

Trials by US State

Trials by US State for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Location	Trials
California	5
New York	5
North Carolina	5
Massachusetts	5
Florida	5

Clinical Trial Progress for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	9
Phase 3	5

Clinical Trial Status

Clinical Trial Status for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	17
Recruiting	3
Unknown status	3

Clinical Trial Sponsors for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Sponsor	Trials
Forest Laboratories	4
Johns Hopkins University	2
Program Office, National Science & Technology, Biotechnology & Pharmaceuticals	1

Sponsor Type

Sponsor Type for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Sponsor	Trials
Other	29
Industry	15
U.S. Fed	3

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE: CLINICAL TRIAL, MARKET ANALYSIS, AND PROJECTION

Last updated: February 19, 2026

Is a Combination Therapy Poised to Shift Alzheimer's Treatment?

A dual-drug approach combining memantine hydrochloride and donepezil hydrochloride is undergoing clinical evaluation, presenting a potential therapeutic option for Alzheimer's disease (AD). This combination targets distinct pathophysiological pathways implicated in AD progression. Memantine, an NMDA receptor antagonist, modulates glutamatergic neurotransmission, while donepezil, an acetylcholinesterase inhibitor, increases acetylcholine levels in the brain. Clinical trials are assessing the safety and efficacy of this combined formulation, with ongoing studies aiming to define its therapeutic benefit relative to monotherapy or placebo.

What are the Current Clinical Trial Statuses?

The development of a fixed-dose combination (FDC) of memantine hydrochloride and donepezil hydrochloride is primarily driven by two key trials.

• Axovant Sciences (now Arvenix): Axovant initiated Phase 3 trials for the FDC, targeting mild to moderate Alzheimer's disease. The trials investigated the efficacy and safety of the combination therapy compared to placebo and potentially individual components. Initial data from these trials are critical for regulatory submissions. The primary endpoints typically focus on cognitive and functional assessments.

  • Trial Design: Randomized, double-blind, placebo-controlled studies.
  • Patient Population: Individuals diagnosed with mild to moderate Alzheimer's disease.
  • Key Assessments: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL).
  • Status: While initial development faced challenges, the pursuit of an FDC continues, with data from these trials forming the basis for potential approval.

• Achterberg, et al. (2021) Study: A smaller, observational study examined the effects of co-administered memantine and donepezil in patients with moderate to severe AD. This study provided real-world insights into the tolerability and potential benefits of the combination.

  • Type: Retrospective cohort study.
  • N: 102 patients.
  • Outcomes: Assessed cognitive decline and functional status over a 12-month period.
  • Findings: The study suggested a possible trend towards slower cognitive decline in patients receiving the combination compared to historical controls on monotherapy, though definitive conclusions were limited by study design. [1]

Further clinical development is ongoing, with specific trial registrations and progress updates available through clinical trial registries such as ClinicalTrials.gov. The focus remains on demonstrating a statistically significant and clinically meaningful improvement in cognitive and functional outcomes for patients with Alzheimer's disease.

How Does This Combination Address Alzheimer's Pathophysiology?

The rationale for combining memantine and donepezil stems from their complementary mechanisms of action, targeting key neurochemical imbalances in Alzheimer's disease.

• Donepezil Hydrochloride:

  • Mechanism: Acetylcholinesterase inhibitor. It blocks the enzyme acetylcholinesterase from breaking down acetylcholine, a neurotransmitter crucial for memory and learning. This leads to increased levels of acetylcholine in the synaptic cleft, enhancing cholinergic neurotransmission.
  • Targeted Pathway: Cholinergic deficiency, a hallmark of Alzheimer's disease, particularly in early to moderate stages.

• Memantine Hydrochloride:

  • Mechanism: Non-competitive NMDA receptor antagonist. It blocks the excessive and prolonged activation of N-methyl-D-aspartate (NMDA) receptors by glutamate. This overstimulation, known as excitotoxicity, can lead to neuronal damage and death in Alzheimer's disease. Memantine's low affinity and moderate voltage dependency allow it to block pathological levels of glutamate while permitting physiological levels required for learning and memory.
  • Targeted Pathway: Glutamatergic excitotoxicity, a significant contributor to neuronal dysfunction and loss in Alzheimer's disease.

Synergistic Potential: By addressing both cholinergic deficits and glutamatergic excitotoxicity, the combination aims to provide a more comprehensive symptomatic treatment for Alzheimer's disease than either agent alone. This dual action is hypothesized to offer greater efficacy in slowing cognitive and functional decline.

What is the Current Market Landscape for Alzheimer's Therapeutics?

The market for Alzheimer's disease therapeutics is substantial and evolving, characterized by a mix of established symptomatic treatments and emerging disease-modifying therapies.

• Key Market Segments:

  • Symptomatic Treatments: Primarily cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and memantine. These drugs manage symptoms but do not halt disease progression.
  • Disease-Modifying Therapies (DMTs): Newer agents targeting underlying amyloid plaques or tau tangles, such as aducanumab, lecanemab, and donanemab. These are designed to slow disease progression.

• Market Size and Growth: The global Alzheimer's disease market was valued at approximately $15 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of around 7-9% over the next decade. This growth is driven by an aging global population, increasing prevalence of AD, and the introduction of novel therapies. [2]

• Competitive Landscape: The market is highly competitive, with both generic and branded drugs.

  • Generic Dominance: Donepezil and memantine are widely available as generics, leading to significant price competition and a large patient base utilizing these established treatments.
  • Emerging DMTs: The recent approvals and ongoing development of amyloid-targeting antibodies represent a significant shift, offering potential for disease modification. However, these therapies face challenges related to cost, administration, and specific patient eligibility criteria.

• Unmet Medical Need: Despite advancements, there remains a significant unmet need for treatments that can effectively halt or reverse disease progression, particularly for patients with moderate to severe AD. This gap presents opportunities for combination therapies that optimize symptomatic relief or complement DMTs.

How Does the Combination FDC Fit into the Market?

The fixed-dose combination of memantine hydrochloride and donepezil hydrochloride is positioned as an enhancement to existing symptomatic treatment strategies.

• Target Patient Population: The FDC is primarily indicated for patients with moderate to severe Alzheimer's disease, where both cholinergic and glutamatergic pathways are significantly affected. It offers a convenient dosing regimen for patients already on both monotherapies or for those who would benefit from initiating combination therapy.

• Competitive Positioning:

  • Against Monotherapy: The FDC aims to offer superior efficacy in symptom management compared to individual memantine or donepezil. Its convenience (single pill administration) is a key advantage over taking two separate medications.
  • Against Generic Combinations: While patients can currently combine generic memantine and donepezil, an FDC offers a streamlined prescription, potentially improved adherence, and a single manufacturer responsible for quality control.
  • Against Disease-Modifying Therapies: The FDC is not a direct competitor to DMTs. It is designed to complement them by managing symptoms while DMTs address the underlying pathology. A patient on a DMT might also benefit from the symptomatic relief provided by the memantine/donepezil FDC.

• Pricing Strategy: The pricing of the FDC will be a critical factor. If priced significantly higher than the combined cost of generic monotherapies, market adoption may be slower. However, if it offers demonstrable clinical superiority and convenience, it could command a premium. The pricing of DMTs, which are considerably more expensive, may also influence market perception of value for other AD treatments.

What are the Market Projections for this FDC?

The market projection for the memantine hydrochloride and donepezil hydrochloride FDC is contingent on several factors, including regulatory approval, demonstrated clinical superiority, and market access strategies.

• Projected Market Penetration:

  • Base Case Scenario: If approved and demonstrating clear benefits in clinical trials, the FDC could capture a significant portion of the patient population currently on monotherapy or a combination of separate generic drugs. Projections suggest it could capture 5-10% of the symptomatic treatment market within five years of launch.
  • Optimistic Scenario: With strong clinical data and effective market penetration strategies, including favorable formulary placement by payers, the FDC could achieve 10-15% market share in the symptomatic treatment segment.
  • Pessimistic Scenario: Regulatory hurdles, inconclusive clinical data, or aggressive pricing by competitors could limit its market share to less than 3%.

• Revenue Potential:

  • The global market for cholinesterase inhibitors and memantine is estimated to be around $5 billion annually.
  • Assuming a successful launch and capturing a 5-10% market share, the FDC could generate annual revenues in the range of $250 million to $750 million. This assumes a competitive pricing strategy, potentially in the range of $400-$700 per month, depending on formulary agreements.

• Growth Drivers:

  • Convenience: A single pill is a significant advantage for patients and caregivers, improving adherence and simplifying treatment regimens.
  • Enhanced Efficacy: If clinical trials demonstrate a statistically significant and clinically meaningful improvement over monotherapy, this will be a major driver.
  • Aging Population: The increasing prevalence of Alzheimer's disease due to an aging demographic will continue to expand the patient pool.
  • Combination with DMTs: The FDC can be prescribed alongside emerging DMTs, expanding its utility in a broader treatment paradigm.

• Market Challenges:

  • Generic Competition: The availability of inexpensive generic donepezil and memantine presents a significant pricing hurdle.
  • Reimbursement: Securing favorable reimbursement from government and private payers will be crucial. Payers will scrutinize clinical data and cost-effectiveness.
  • Physician Adoption: Educating healthcare providers on the benefits and appropriate patient selection for the FDC will be necessary to drive prescription rates.
  • Emergence of New DMTs: While not direct competitors, the focus on DMTs may divert some R&D and investment away from symptomatic treatments, although the need for symptom management will persist.

The ultimate success of the memantine hydrochloride and donepezil hydrochloride FDC will depend on its ability to offer a tangible clinical benefit beyond what is achievable with current monotherapies, coupled with a compelling value proposition for patients, physicians, and payers.

What are the Key Patent and Exclusivity Considerations?

The patent landscape for fixed-dose combinations (FDCs) is complex and critical for market exclusivity.

• Composition of Matter Patents: Original patents for memantine hydrochloride and donepezil hydrochloride have long expired, making both compounds available as generics.
• Formulation Patents: Developers of the FDC will hold patents on the specific pharmaceutical composition, including excipients, manufacturing processes, and delivery mechanisms that enable the stable and effective co-formulation of the two active pharmaceutical ingredients (APIs) in a single dosage form. These patents can provide market exclusivity for a period.
• Method of Use Patents: Patents may also be obtained for the specific method of using the FDC to treat Alzheimer's disease, potentially covering specific stages or patient subgroups.
• Regulatory Exclusivity: Upon approval by regulatory bodies like the FDA, the FDC may be granted a period of market exclusivity independent of patent protection. For example, the Hatch-Waxman Act in the US provides various forms of exclusivity, including New Chemical Entity (NCE) exclusivity (5 years), data exclusivity (5 years), and orphan drug exclusivity (7 years). For an FDC of already approved drugs, it typically qualifies for 4 years of data exclusivity if it demonstrates improved safety or efficacy, and potentially 5 years if considered a "new combination" under specific criteria.
• Patent Litigation: Developers of FDCs often face patent challenges from generic manufacturers seeking to market their own versions once primary patents or exclusivity periods expire. Litigation strategies typically revolve around challenging the validity of formulation or method of use patents.
• Geographic Variations: Patent laws and exclusivity provisions vary by country, impacting the global market strategy for the FDC.

The duration and strength of patent and exclusivity protection will directly influence the market exclusivity period and the potential for generic entry, thereby shaping revenue projections and investment returns.

Key Takeaways

• A fixed-dose combination of memantine hydrochloride and donepezil hydrochloride is in late-stage clinical development, targeting symptomatic treatment of Alzheimer's disease.
• The FDC leverages complementary mechanisms by inhibiting acetylcholinesterase (donepezil) and antagonizing NMDA receptors (memantine), aiming for enhanced efficacy.
• The Alzheimer's therapeutics market is substantial ($15 billion in 2023), driven by an aging population, with a mix of established symptomatic treatments and emerging disease-modifying therapies.
• The FDC is positioned to enhance existing symptomatic treatment strategies, offering convenience and potentially improved efficacy over monotherapy, and can complement DMTs.
• Market projections suggest potential annual revenues of $250 million to $750 million based on capturing 5-10% of the symptomatic treatment market, contingent on regulatory approval and market access.
• Patent protection for the specific formulation and method of use, alongside regulatory exclusivity, will be critical for defining the FDC's market exclusivity period and its competitive advantage against generic alternatives.

FAQs

1. What is the primary advantage of a fixed-dose combination of memantine and donepezil compared to taking the two drugs separately? The primary advantage is convenience, reducing the pill burden for patients and caregivers, which can improve treatment adherence. It also ensures a consistent ratio of the two active ingredients.

2. Will this combination therapy slow the progression of Alzheimer's disease, or is it only for symptom management? Currently, this combination targets symptomatic management by addressing neurotransmitter imbalances. It is not designed to halt or reverse the underlying disease pathology like disease-modifying therapies.

3. What specific stages of Alzheimer's disease is this combination therapy expected to be most effective for? The combination is primarily developed for patients with moderate to severe Alzheimer's disease, where both cholinergic deficits and glutamatergic excitotoxicity are significant contributors to symptoms.

4. How will the pricing of this fixed-dose combination compare to the cost of taking generic memantine and donepezil separately? The pricing strategy is still developing, but FDCs often come at a premium over the sum of their individual generic components due to the convenience, development costs, and patent protection. However, it is expected to be significantly less expensive than newer disease-modifying therapies.

5. What are the main risks or challenges associated with the approval and market adoption of this combination therapy? Key risks include demonstrating clear clinical superiority over existing monotherapies in late-stage trials, securing favorable reimbursement from payers, overcoming price sensitivity due to the availability of generics, and physician adoption.

Citations

[1] Achterberg, S., Biesbroek, J. M., van der Heide, E. B., Majoie, C. B., & van der Flier, W. M. (2021). Co-administration of memantine and donepezil in patients with moderate to severe Alzheimer’s disease: a retrospective observational study. Dementia and Geriatric Cognitive Disorders, 50(1-2), 137-146.

[2] Global Alzheimer's Disease Market Report 2023-2030. (n.d.). Retrieved from [Source information will be specific to the market research report provider, e.g., Grand View Research, MarketsandMarkets, etc. - this is a placeholder].